Psilocybin is the main psychoactive ingredient in hallucinogenic mushrooms, also called "magic mushrooms" or "shrooms." There are over 100 species of mushrooms that contain psilocybin.
Although people have been consuming magic mushrooms for thousands of years, the compound wasn't isolated until 1957 and it was produced synthetically a year later. Since 1970, psilocybin and psilocin (a closely related compound) have been listed by the U.S. Drug Enforcement Association (DEA) as Schedule I substances the federal government's most restrictive category.
Despite these restrictions, recent clinical trials have found psilocybin to be a promising therapy for treatment-resistant anxiety and depression. Because of this, the U.S. Food and Drug Administration (FDA) has designated psilocybin as a "breakthrough therapy" an action meant to accelerate the drug development and review process.
There are over 100 species of psilocybin-containing mushrooms with varying potencies, said Matthew Johnson, an associate professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine in Baltimore who studies psychedelic drugs such as psilocybin.
Psilocybin mushrooms have long, slender stems topped by caps with dark brown edges, according to the DEA. In the U.S., magic mushrooms are found in the Southeast and Pacific Northwest often growing in pastures on cow dung, Johnson told Live Science. They also grow in Mexico, Central and South America. The most potent species in the world is considered Psilocybe azurescens, which is found mainly in the U.S. Pacific Northwest.
In the early 1950s, an American banker and mushroom enthusiast named R. Gordon Wasson came across an indigenous tribe using psychoactive mushrooms when he was on vacation in Mexico, according to Drug Policy Alliance. Wasson sent samples of the mushrooms to Albert Hoffmann, a Swiss chemist known for discovering LSD. Hoffmann isolated psilocybin from the mushroom Psilocybe mexicana in 1957, and he developed a way to produce a synthetic version of the psychedelic compound a year later.
Since 1970, psilocybin and psilocin have been listed by the DEA as Schedule I substances, the federal government's most restrictive category. Drugs in this category are believed to have a "high potential for abuse" as well as "no accepted medical use," according to the DEA.
Psilocybin along with other drugs, such as lysergic acid diethylamide (LSD) and mescaline, are considered "classic psychedelics" because they can induce changes in mood, thought and perception by mimicking neurotransmitters in your brain.
Once it enters the body, psilocybin is broken down into psilocin, a substance that acts like the neurotransmitter serotonin, which regulates mood. Psilocybin is known to activate a specific type of serotonin receptor in the brain that triggers its psychedelic effects, Johnson said.
Its hallucinatory effects can cause a person to see images, hear sounds and feel sensations that seem real but aren't, according to Partnership for Drug-Free Kids. Someone on psilocybin may experience synesthesia, or the mixture of two senses, such as feeling like they can smell colors.
Related: 'Trippy' bacteria engineered to brew 'magic mushroom' hallucinogen
Besides sensory enhancement and visual hallucinations, participants in psilocybin-assisted therapy sessions have described the drug's effects as a life-changing experience where they gain deep insight that shifts the way they think about themselves.
A mystical type of experience has also been linked with the use of psilocybin, Johnson said. People have described feeling at one with humanity, feeling a sense of unity, and feeling a sense of self dissolve after consuming the psychedelic compound, he explained.
Studies have shown that after taking psilocybin, there is a sharp increase in communication between areas of the brain that normally don't talk to each other, which may partly explain the new insights people experience. There's also a quieting of deeply entrenched thought patterns that contribute to addictions, anxiety and depression, Johnson said.
People have been ingesting psilocybin-containing mushrooms for thousands of years as part of religious ceremonies or for healing purposes.
Magic mushrooms can be made into a tea, eaten raw or dried, ground into a powder and put in capsules, or coated in chocolate, to mask their bitter flavor and disguise them as candy, Johnson said. The hallucinogenic effects may begin within 20 to 40 minutes of use and last about 3 to 6 hours, according to the U.S. Department of Justice.
Studies on the possible medical benefits of psilocybin and other psychedelics began in the 1950s and '60s, immediately after Hoffmann created a way to produce the chemical synthetically.
Although findings showed promise for treating anxiety, depression and addiction, research in the U.S. came to a halt in 1970, when President Richard Nixon signed the Controlled Substances Act. This law was viewed as a political response to a growing fear of psychedelic drug use in young people and the spread of the counterculture movement.
Three decades later, Roland Griffiths, a psychopharmacologist at Johns Hopkins, won FDA approval to study psilocybin, ushering in a new era of psychedelics research with more rigorous scientific standards than earlier studies.
When used in current research sessions, participants take a pill containing a high dose of synthetic psilocybin with professionals monitoring them and providing psychological support, Johnson said. They typically receive counseling before and after the psychedelic experience.
The FDA has granted some scientists permission to use psilocybin in research but the recreational use of psilocybin is illegal in the U.S. However, its illicit use has been decriminalized in two cities (Denver and Oakland, California) and other cities are working on similar measures, Johnson said.
Psilocybin has shown promise for treating a variety of difficult-to-treat health conditions.
For example, the results are extremely positive for the use of psilocybin in the treatment of smoking cessation and depression, Johnson said. Recent clinical trials have reported that just one to three doses of psilocybin given in conjunction with cognitive behavioral therapy have helped patients quit their smoking habit, he said. Afterward, people feel more confident in their ability to change behavior and manage their addictions.
Results are also promising for the use of psilocybin in reducing cancer-related anxiety and treatment-resistant depression two areas where there is a huge need for better treatment options, Johnson said.
Psilocybin along with supportive therapy appears to help people come to grips with problems and learn from these experiences, he said. The treatment may induce insights and novel perspectives that promote mental flexibility and may cause lasting behavior changes six months to a year later.
Small studies of psilocybin have also suggested benefits as a treatment for alcohol addiction and obsessive-compulsive disorder.
The most common negative side effect of psilocybin is the potential for a "bad trip," Johnson said. High doses of psilocybin can cause overwhelming feelings of anxiety, fear and confusion that can lead to dangerous behavior if not used under medical supervision.
Psychedelics are very intoxicating substances, and their side effects can be challenging to manage even in the relatively safe framework of a research setting, Johnson said. Researchers reduce these risks by prohibiting people with a history of psychosis from participating in psilocybin studies. Psilocybin can also moderately increase blood pressure, which is why people with heart problems are excluded from studies, he added. Other possible side effects of psilocybin use include nausea, vomiting, headaches and stomach cramps.
For recreational users, misidentification of mushroom species is one of the biggest concerns. Some poisonous varieties of mushrooms in the wild bear a strong resemblance to psilocybin species, according to ProjectKnow. Inexperienced mushroom hunters might not recognize the difference, and could accidentally ingest a poisonous mushroom, which could lead to liver failure or death.
This article is for informational purposes only, and is not meant to provide medical advice.
Here is the original post:
- The Psychedelic Renaissance with the former VP of content at High Times (Brains Byte Back podcast) - The Sociable - May 19th, 2020
- Psychedelic experiences disrupt routine thinking and so has the coronavirus pandemic - The Conversation CA - May 19th, 2020
- Have a Good Trip Demystifies Psychedelics - The New Republic - May 19th, 2020
- Psilocybin: An Effective Treatment for Weight Loss and Food Craving? - Yahoo Finance - May 19th, 2020
- This Trippy Oregon Theme Park Is Like A Psychedelic Disneyland - Thrillist - May 19th, 2020
- Novamind and Buzz Capital Announce Qualifying Transaction TSX Venture Exchange:BUZ-P - GlobeNewswire - May 19th, 2020
- REPEAT - Champignon Sponsors Non-profit Coalition, TheraPsil - Medical Psilocybin Access Project for Palliative Cancer Patients and Health... - May 19th, 2020
- Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives - GlobeNewswire - May 19th, 2020
- Celebrities share LSD trips in Netflix documentary 'Have A Good Trip' - Insider - INSIDER - May 5th, 2020
- Netflix And Trip: Take A Psychedelic Adventure In This Star-Studded Documentary - Forbes - May 5th, 2020
- Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week - Benzinga - May 5th, 2020
- Have a Good Trip Review: Netflix LSD Doc Is Way Too High on Its Own Supply - IndieWire - May 5th, 2020
- Entheon Biomedical CEO Timothy Ko On The Potential Of Psychedelics In Addiction Treatment - Benzinga - May 5th, 2020
- Netflix Reveals Celebrities' Wildest Drug Trips, From Anthony Bourdain to Carrie Fisher - The Daily Beast - May 5th, 2020
- The 'Billions' Stock Watch: It's Time For Psychedelics And Subterfuge - UPROXX - May 5th, 2020
- Prohibition Partners Teams Up With Mazakali For Live Investor Event - Green Market Report - May 5th, 2020
- Psychedelics - Alcohol and Drug Foundation - March 26th, 2020
- Psychedelics - Mushrooms, LSD, Salvia - March 26th, 2020
- The 12 Most Popular Psychedelic Drugs | Ocean Breeze Recovery - March 26th, 2020
- Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week - Yahoo Finance - March 26th, 2020
- Green Rush Podcast: Bruce Linton On Psychedelics, Listing On The NEO, And The Difference Between 'Going Public' And 'Being Public' - Benzinga - March 26th, 2020
- Microdosing: taking illegal psychedelic drugs as a form of therapy - does it actually work? - Now To Love - March 26th, 2020
- Are Investors Ready To Change Their Minds About Psychedelic Drugs? - Forbes - January 30th, 2020
- What ongoing research suggests about psychedelics ability to improve mental health - FOX 59 Indianapolis - January 30th, 2020
- Could psychedelics help us resolve the climate crisis? - The Conversation UK - January 30th, 2020
- Psychedelic therapy benefits persist five years after treatment - New Atlas - January 30th, 2020
- Synthetic psychedelic drug effective in reducing alcohol intake in a rodent model of addiction - PsyPost - January 30th, 2020
- What it's like to take part in a psychedelic retreat - The Independent - January 30th, 2020
- Volunteers push to legalize the therapeutic uses of psychedelic mushrooms - Daily Astorian - January 30th, 2020
- Canadian psychedelic drug researcher featured in Paltrows Netflix show The Goop Lab - The Globe and Mail - January 30th, 2020
- 5 years after taking one dose of magic mushrooms, a gaggle of most cancers sufferers nonetheless really feel much less despair and nervousness -... - January 30th, 2020
- What is Psychedelic Psychotherapy? Does it Really Work? Is The Goop Lab Fake? - The Cinemaholic - January 30th, 2020
- Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health - Forbes - January 16th, 2020
- Can you have a bad trip from taking acid in the woods? - WHYY - January 16th, 2020
- How researchers and advocates of color are forging their own paths in psychedelic-assisted therapy - WHYY - January 16th, 2020
- NYC To Host Economics Of Psychedelics Investing Summit - Benzinga - January 16th, 2020
- A CIA chemist, mind control and the return of psychedelic drugs - The Boston Globe - January 13th, 2020
- Gwyneth Paltrow's New Netflix Docuseries Is Full of Psychedelics and Orgasms - Vogue - January 13th, 2020
- Syd Barrett: How LSD Created and Destroyed His Career With Pink Floyd - Biography - January 13th, 2020
- Psychadelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health - Forbes - January 12th, 2020
- Editorial: Psychonaut of the week - Echonetdaily - January 12th, 2020
- Rats on DMT hint at the benefits of psychedelic microdosing - Inverse - January 5th, 2020
- Psychedelic Drugs: Researchers experimenting with active agent in magic mushrooms to treat addiction, depression and anxiety - 60 Minutes - CBS News - January 5th, 2020
- Psychedelics Were Already Having a Good Year. Then Andrew Yang Tweeted - VICE - December 23rd, 2019
- Psychedelics and Wellness: What's the Connection? - Psych Congress Network - December 23rd, 2019
- Bruce Linton Talks Psychedelics Investments, Microdosing And LSD: 'The Therapeutic Potential Of Psychedelics Is Greater Than Cannabinoids' - Benzinga - December 23rd, 2019
- Why Doctors Are Turning to Psychedelics to Treat Depression & Addiction - Men's Journal - December 23rd, 2019
- Anxiety, depression and the new science of psychedelics part two - ABC News - November 13th, 2019
- Keeno Ahmed-Jones: Getting out of the psychedelic closet - Straight.com - November 13th, 2019
- Call for patients to take part in anorexia psilocybin treatment study - Health Europa - November 13th, 2019
- The Two Black Women Helping To Reclaim & Encourage Natural Psychedelics Use In Oakland - Okayplayer - October 29th, 2019
- Shirola: U.S. government should ease legal barriers to research and treatment with psychedelics - Daily Northwestern - October 29th, 2019
- Molecule Catalyst and UTM to crowdfund psychedelics research with blockchain - Decrypt - October 29th, 2019
- Psilocybin: Active agent in magic mushrooms could treat addiction, depression and anxiety - 60 Minutes - CBS News - October 16th, 2019
- Psilocybin: 5 Fast Facts You Need to Know - Heavy.com - October 16th, 2019
- Psychedelic Toad Venom Is the New Trendy Hallucinogenic - Addiction Center - October 16th, 2019
- What You Can Learn From Snorting Two Lines of LSD - TheStranger.com - October 1st, 2019
- The second coming of psychedelics in pop culture - Happy Mag - October 1st, 2019
- Exploring the changing relationship between sex and drugs - Dazed - October 1st, 2019
- How to Safely Use LSD - How to Use Psychedelics - June 3rd, 2019
- How to Treat Depression with Psychedelics - April 20th, 2019
- Can You Take Psychedelics With Antidepressants? - April 20th, 2019
- Beginners Guide to Microdosing Psychedelics - April 20th, 2019
- Learn Everything You Need To Know About MDMA (Ecstasy) - April 20th, 2019
- Psychedelic drug - Wikipedia - March 1st, 2019
- Psychedelic art - Wikipedia - February 19th, 2019
- Psychedelic Drugs and the Serotonergic System - February 19th, 2019
- How to Use MDMA (Molly) - How to Use Psychedelics - February 19th, 2019
- How to Take Mushrooms (Psilocybin mushrooms / Shrooms ... - February 19th, 2019
- Tim Ferriss: depression, psychedelics, and emotional ... - January 7th, 2019
- Psychedelics - Pharmacological Reviews - December 18th, 2018
- Psychedelia - Wikipedia - December 18th, 2018
- A Microdose Of “Magic Mushrooms” Could Unleash Your Creativity - October 29th, 2018
- Famous Users of Psychedelics - How to Use Psychedelics for ... - June 14th, 2018
- How to Use MDMA - June 9th, 2018
- Psychedelics - PsychonautWiki - May 28th, 2018
- Microdosing: The Revolutionary Way of Using Psychedelics ... - May 25th, 2018
- The Truth About What Psychedelics Do to Your Brain - May 17th, 2018
- Do Psychedelics Carry A Heart Risk? - The Third Wave - May 4th, 2018
- 6 facts about psychedelic drugs that will totally blow ... - April 24th, 2018